Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
| ▸ | SCN1A | P35498 | 1/20 | 0.74 |
| ▸ | HTR2B | P41595 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.74 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | HRH2 | P25021 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14724514 | 0.95 | HRH3 (0.71) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL28126773 | 0.95 | HRH3 (0.68) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL16314572 | 0.94 | ALDH1A1 (0.66) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL18763519 | 0.93 | HRH3 (0.65) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL374497 | 0.92 | LTA4H (0.67) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL2385707 | 0.90 | NPC1 (0.68) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL14742325 | 0.90 | NPC1 (0.68) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL14204158 | 0.90 | CA12 (0.65) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL24398699 | 0.89 | TSHR (0.76) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL22609310 | 0.89 | LTA4H (0.65) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. | 2025-06-12 | — | — | US | disclosed |
| EP-4486348-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804751-A | New compounds and treatment of renal cell carcinoma | 巴什生物技术公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-116120300-B | Pyrimidine compound containing hydroxamic acid fragment, and preparation method and application thereof | 贵州大学 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-114716366-B | 3-hydroxypyridin-4-one derivatives and application thereof in inhibiting iron death of renal cells | 浙江大学 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023166153-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC (US) | 2023-09-07 | — | — | WO | disclosed |
| CN-116120300-A | Pyrimidine compound containing hydroxamic acid fragment, and preparation method and application thereof | 贵州大学 | 2023-05-16 | — | — | CN | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-7060827-B2 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | HRH3 22/4885MAPK1 581/4885ALDH1A1 2891/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | HRH3 25/4885MAPK1 1201/4885ALDH1A1 2723/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | HRH3 16/4885MAPK1 1247/4885ALDH1A1 2615/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | HRH3 131/4885MAPK1 434/4885ALDH1A1 2302/4885 |
| US-20250188041-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | RCC2, GLS, VHL | HRH3 3810/4885MAPK1 1240/4885ALDH1A1 208/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | HRH3 22/4885MAPK1 581/4885ALDH1A1 2891/4885 |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | SYK, FCER2, FCGR1A | HRH3 65/4885MAPK1 233/4885ALDH1A1 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.